相关实验视频

Updated: Jul 5, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

拉姆诺斯修饰抗体显示出对EGFR阳性固体瘤细胞的免疫杀伤有所改善

Haofei Hong¹, Jie Zhao¹, Kun Zhou¹

¹Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.

Carbohydrate research

|January 14, 2024

概括

研究人员使用拉姆诺斯 (Rha) 功能化增强了针对表皮生长因子受体 (EGFR) 的治疗抗体. 这种修改改善了效应器功能,增强了对固体瘤的癌症免疫治疗潜力.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

针对表皮生长因子受体 (EGFR) 的治疗单克隆抗体 (mAbs) 对结直肠和其他固体癌症有效.
增强抗EGFR mAbs的效应器功能是提高临床疗效的关键策略.

研究的目的:

通过rhamnose (Rha) 功能化开发一种效应器功能增强的抗体.
为了研究Rha结合对抗瘤活性 cetuximab 的影响,一个抗EGFR mAb.

主要方法:

拉姆诺斯 (Rha) 哈普顿与 cetuximab 的特定位点的结合.
评估 cetuximab-Rha结合剂将内源抗Rha抗体重定向到EGFR阳性瘤细胞的能力.
评估增强的效应因子功能,包括补充依赖的细胞毒性 (CDC) 和抗体依赖的细胞介导细胞症 (ADCP).

主要成果:

塞图西马布-Rha结合剂成功地将内源抗体重定向到EGFR阳性瘤细胞.
显著增强效应因子功能,特别是补剂依赖性细胞毒性 (CDC),此前在 cetuximab 中不活跃.
已证明改善了抗体依赖细胞介导的细胞分裂 (ADCP).

结论:

拉姆诺斯功能化是一种可行的策略,可以增强治疗抗体 (如 cetuximab) 的效应器功能.
开发的修改为拉姆诺斯的抗体显示出改善EGFR阳性固体瘤免疫疗法的潜力.
这种方法提供了一种新的方法来提高现有的基于抗体的癌症疗法的疗效.

关键词:

在ADCP中,ADCP是ADCP.这就是为什么CDC CDC CDC.这种药物是Cetuximab.欧洲农业基金会 (EGFR) 是一个.拉姆诺斯 (Rhamnose) 是一个名字.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...